Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2017 Mar 26;7(1):9-15.
doi: 10.5662/wjm.v7.i1.9.

Chromogranin A as a valid marker in oncology: Clinical application or false hopes?

Stavros Gkolfinopoulos  1 , Konstantinos Tsapakidis  1 , Konstantinos Papadimitriou  1 , Demetris Papamichael  1 , Panteleimon Kountourakis  1
Affiliations
Review

Chromogranin A as a valid marker in oncology: Clinical application or false hopes?

Stavros Gkolfinopoulos et al. World J Methodol. .

Abstract

Chromogranin A, due to its primary expression throughout the neuroendocrine system, is a widely accepted biomarker for the assessment of neuro-endocrine tumors. It has been traditionally used in the management of patients with tumors of gastro-enteropancreatic origin. Lately, it has also been implicated in various conditions and diseases, both benign and malignant. However, the paucity of data of adequate strength, as well as its relation with common physiologic conditions and its interaction with commonly prescribed medications, limit its clinical use in only a narrow spectrum. Herein, we present a thorough review to the most frequent conditions where its levels are affected, focusing specifically on its potential use as a prognostic and predictive biomarker in oncology.

Keywords: Biomarker; Cancer; Chromogranin A; Neuroendocrine tumors; Prognosis.

PubMed Disclaimer

Conflict of interest statement

Conflict-of-interest statement: There is no conflict of interest on the part of any other authors on this study.

References

    1. Taupenot L, Harper KL, O’Connor DT. The chromogranin-secretogranin family. N Engl J Med. 2003;348:1134–1149. - PubMed
    1. Eriksson B, Arnberg H, Oberg K, Hellman U, Lundqvist G, Wernstedt C, Wilander E. A polyclonal antiserum against chromogranin A and B--a new sensitive marker for neuroendocrine tumours. Acta Endocrinol (Copenh) 1990;122:145–155. - PubMed
    1. Helle KB. Chromogranins A and B and secretogranin II as prohormones for regulatory peptides from the diffuse neuroendocrine system. Results Probl Cell Differ. 2010;50:21–44. - PubMed
    1. Campana D, Nori F, Piscitelli L, Morselli-Labate AM, Pezzilli R, Corinaldesi R, Tomassetti P. Chromogranin A: is it a useful marker of neuroendocrine tumors? J Clin Oncol. 2007;25:1967–1973. - PubMed
    1. Deftos LJ. Chromogranin A: its role in endocrine function and as an endocrine and neuroendocrine tumor marker. Endocr Rev. 1991;12:181–187. - PubMed